Epimedium, commonly sold as horny goat weed, has raised testosterone levels in animal studies, but no published human clinical trials confirm the same effect in people. The active compound, icariin, has increased testosterone production in rats at moderate to high doses, and lab studies show it can stimulate the cells responsible for making testosterone. The gap between those findings and what happens when you swallow a supplement is significant.
What Animal Studies Actually Show
The strongest evidence comes from rat studies. In one widely cited experiment published in the journal Molecules, male rats given icariin at doses of 50 to 100 mg per kilogram of body weight showed statistically significant increases in serum testosterone. The effect was dose-dependent: higher doses produced greater increases. Researchers confirmed that icariin boosted testosterone production by switching on specific genes (StAR and PBR) that control the early steps of hormone synthesis inside Leydig cells, the testosterone-producing cells in the testes.
A separate study in aging mice found that icariin restored testosterone levels that had declined with age. The compound activated a signaling chain (involving estrogen receptor alpha and the AKT pathway) that restarted testosterone synthesis while also reducing oxidative damage to testicular tissue. In other words, it appeared to protect the cells that make testosterone and simultaneously coax them back into producing more of it.
These are real, measurable hormonal changes. But they happened in rodents receiving purified icariin at doses far higher, relative to body weight, than what most supplements deliver.
Why the Human Evidence Is Missing
No controlled human trial has measured testosterone levels before and after epimedium supplementation. That’s a critical gap. Animal metabolism, hormone regulation, and drug absorption differ enough from humans that positive rat data routinely fails to translate. Many compounds that raise testosterone in rodents do nothing measurable in people.
One reason for skepticism is bioavailability. When you take icariin by mouth, only about 12% of it reaches your bloodstream. The compound dissolves poorly in water and passes through intestinal membranes slowly. That means the vast majority of what you swallow never gets to the cells where testosterone is made. Researchers are experimenting with lipid nanoparticle delivery systems to improve absorption, but these aren’t available in consumer supplements.
PDE5 Inhibition: A Separate Effect
Much of epimedium’s reputation for improving sexual function likely comes from a mechanism that has nothing to do with testosterone. Icariin inhibits PDE5, the same enzyme targeted by prescription erectile dysfunction drugs. It also promotes nitric oxide production in smooth muscle tissue, which improves blood flow. These effects can enhance erectile function without changing hormone levels at all.
This distinction matters because many people interpret improved libido or sexual performance as evidence that their testosterone went up. In reality, icariin may be acting more like a mild, natural version of a PDE5 inhibitor. The sexual benefits some users report could be vascular, not hormonal.
Icariin Also Raises Estrogen
One finding that rarely makes it into supplement marketing: icariin increases estrogen levels too. Research has shown that icariin induces aromatase expression, the enzyme that converts testosterone into estradiol. In ovariectomized rats, icariin treatment raised circulating estradiol. This estrogenic activity is well-documented and is actually the basis for research into icariin as a potential treatment for osteoporosis in postmenopausal women.
For someone taking epimedium specifically to raise testosterone, boosting aromatase activity could be counterproductive. More aromatase means more testosterone gets converted to estrogen, potentially offsetting any gains in testosterone production. This dual hormonal effect makes the net outcome in humans genuinely unpredictable without clinical data.
Supplement Dosing Versus Research Dosing
Most epimedium supplements contain extracts standardized to 10% or 20% icariin, delivering somewhere between 50 and 200 mg of icariin per capsule. Research studies, by contrast, have used purified icariin at 98.8% concentration. One animal study found that very low doses (1 mg/kg) were surprisingly effective, sometimes matching or exceeding higher doses, which complicates simple dose-response assumptions.
Even if you could match the effective dose from rat studies, the 12% oral bioavailability means your body absorbs a fraction of what you take. A 500 mg epimedium capsule standardized to 10% icariin delivers 50 mg of icariin, of which roughly 6 mg reaches your bloodstream. Whether that amount can meaningfully influence testosterone production in a human male is completely unknown.
Known Side Effects
Epimedium is generally tolerated at typical supplement doses, but reported side effects include dizziness, dry mouth, nosebleed, thirst, and vomiting. The Mayo Clinic notes that the herb may affect heart rhythm or breathing, which is particularly relevant for anyone with cardiovascular disease or diabetes. Because icariin has both estrogenic and androgenic activity, people with hormone-sensitive conditions should be cautious.
Long-term safety data in humans doesn’t exist. Most supplement use is self-directed, with no monitoring of hormone panels, liver function, or cardiovascular markers over time.
The Bottom Line on Testosterone
Icariin can increase testosterone production in isolated cells and in living animals. The biological mechanisms are real and well-characterized. But the compound’s poor oral absorption, its simultaneous estrogen-boosting effects, and the complete absence of human testosterone data make it impossible to say that taking an epimedium supplement will raise your testosterone levels. The sexual function benefits that users report are more plausibly explained by PDE5 inhibition and improved blood flow than by hormonal changes.